Filing Flows › Vir Biotechnology (VIR) › Q1 2025
Vir Biotechnology (VIR) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Vir Biotechnology (VIR) reported revenue of $3.0M for the first quarter 2025 (Q1 2025), -95% from a year earlier and -75% from the quarter before.
Vir Biotechnology, Q1 2025: revenue $3.0M (-95% year over year), net loss $121M, operating cash flow −$78.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -75% | -95% |
| Operating profit | −$140M | — | — |
| Net earnings | −$121M | — | — |
| Operating cash flow | −$78.1M | — | — |
What changed
Revenue was $3.0M in Q1 2025, down 95% year over year and down 75% from the previous quarter.
Operating costs exceeded revenue by $139.5M, an operating margin of -4602.5%. Total costs grew 4% against a revenue fall of 95%. The fastest-growing cost line was Research & development (+18%). The quarter ended with a net loss of $121.0M, wider than the previous quarter's $104.6M loss.
Operating cash flow was −$78.1M. Non-cash charges added back $2.9M of depreciation and amortization and $14.1M of share-based compensation. Working capital and other items added $25.9M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$79.7M.
Questions
What was Vir Biotechnology's revenue in the first quarter 2025?
Vir Biotechnology (VIR) reported revenue of $3.0M for the first quarter 2025 (Q1 2025), -95% from a year earlier and -75% from the quarter before.
Source: Vir Biotechnology 10-Q on SEC EDGAR.